Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR | Market Cap | 1.32B -14.9% |
| Revenue (ttm) | 218.64M +15.5% |
| Net Income | 56.13M +33.6% |
| EPS | 3.11 +29.1% |
| Shares Out | 17.34M |
| PE Ratio | 24.47 |
| Forward PE | 18.07 |
| Dividend | 1.00 (1.20%) |
| Ex-Dividend Date | Jul 8, 2026 |
| Volume | 12,847 |
| Open | 77.00 |
| Previous Close | 76.15 |
| Day's Range | 75.95 - 77.00 |
| 52-Week Range | 64.00 - 105.20 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 102.94 (+35.0%) |
| Earnings Date | Oct 27, 2026 |
About Pharma Mar
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to... [Read more]
Financial Performance
In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PHM stock is "Buy." The 12-month stock price target is €102.94, which is an increase of 35.00% from the latest price.
News
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Pharma Mar Earnings Call Transcript: Q2 2026
Recurring revenues grew strongly in H1 2026, driven by Zepzelca's U.S. royalties and early European launch, offsetting prior year non-recurring items. Cash flow and net cash improved, with rapid EU market access and further revenue growth expected in H2.
Pharma Mar Quarterly report: Q2 2026
Pharma Mar has published its Q2 2026 quarterly earnings report on July 30, 2026.
Pharma Mar Earnings release: Q2 2026
Pharma Mar released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan
Chardan lowered the firm’s price target on Pharma Mar (PHMMF) to EUR 100 from EUR 120 and keeps a Buy rating on the shares after the Phase III LAGOON trial…
Pharma Mar Quarterly report: Q1 2026
Pharma Mar has published its Q1 2026 quarterly earnings report on April 29, 2026.
Pharma Mar Earnings release: Q1 2026
Pharma Mar released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Pharma Mar initiated with a Buy at BTIG
BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current valuation is anchored by a “profitable, cash-generative commercial base” driven by Zepzelca’s…
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Pharma Mar Earnings Call Transcript: Q4 2025
2025 saw 27% revenue growth, a fivefold EBITDA increase, and major milestones for Zepzelca, including U.S. first-line approval. Strong cash flow and pipeline progress position the company for further growth in 2026.
Pharma Mar Earnings release: Q4 2025
Pharma Mar released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Pharma Mar Slides: Q4 2025
Pharma Mar has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
Pharma Mar Earnings release: Q3 2025
Pharma Mar released its Q3 2025 earnings on October 30, 2025, summarizing the period's financial results.
Pharma Mar Quarterly report: Q3 2025
Pharma Mar has published its Q3 2025 quarterly earnings report on October 30, 2025.
Pharma Mar downgraded to Neutral from Outperform at Oddo BHF
Oddo BHF analyst Juan Ros Padilla downgraded Pharma Mar to Neutral from Outperform with a EUR 48 price target
Pharma Mar initiated with a Buy at Chardan
Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites the potential of the company’s lead commercial drug, Zepzelca targeting small cell…
Pharma Mar upgraded to Outperform from Neutral at Oddo BHF
Oddo BHF upgraded Pharma Mar to Outperform from Neutral with a EUR 48 price target. The company’s lung cancer drug Zepzelca has a lot of potential and the stock’s current…